New marketing authorization for indication newly diagnosed DIPG, recurrent/refractory DIPG, locally advanced or metastatic pancreatic cancer is approved in Chile.

Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015 Bandung, Indonesia (Augus 26, 2015) – Innokeys Pte Ltd attended the…

New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.   The…

Application for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…

Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…

Kowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….

New patent is granted with the title of “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR”…